Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epibatidine is a potent piperidine alkaloid originally isolated from the skin of the Ecuadorian poison frog Epipedobates anthonyi (formerly Epipedobates tricolor). It acts as a highly potent analgesic—at least 200 times more powerful than morphine—but its therapeutic window is extremely narrow due to severe toxicity at doses only slightly above those required for pain relief[4][5][10]. Unlike most traditional analgesics that target opioid receptors, epibatidine is a full agonist at neuronal nicotinic acetylcholine receptors (nAChRs), especially subtypes alpha4/beta2 and alpha3/beta2[4][5]. It also binds to other nAChRs in the brain and neuromuscular junctions throughout the body, which can result in adverse effects such as seizures, hypertension, bradycardia, muscular paresis, and potentially fatal respiratory paralysis[4][5]. The compound has been studied primarily in animal models; its high toxicity has precluded clinical development as an analgesic in humans. Research into safer analogs continues due to its unique mechanism of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epibatidine.